secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gain Therapeutics, Inc. (GANX)
CIK:        0001819411
Form:       8-K
Filed at:   2023-11-22T23:59:59+00:00
Accession:  0001104659-23-120819
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gain Therapeutics prices $9.4M public offering and concurrent private placement of common stock and warrants
--------------------------------------------------------------------------------

- Public offering of 2,213,044 shares and 1,106,522 warrants at $2.005/unit; warrants exercisable at $2.75 for 5 years.
- Concurrent private placement for $5.0M: common/pre-funded warrants and warrants for 2,500,088 shares at $2.00.
- Aggregate gross proceeds $9.4M; net proceeds expected ~$8.35M after fees.
- Proceeds to fund GT-02287 development for GBA1 Parkinson's and general corporate purposes.
- Newbridge Securities sole underwriter; closing expected Nov 24, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819411/000110465923120819/0001104659-23-120819-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819411/000110465923120819/tm2330139d3_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-120819

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer